-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A #liquidbiopsy used to monitor progress for patients treated with advanced solid tumors was also found to detect individuals with a high risk of developing #myeloid malignancies: https://t.co/Fxzb8cC5Dk #HemOnc https://t.co/hhLdnQhMea
-
-
Mashup Score: 8
Single-cell transcriptomic profiling of the bone marrow of a TET2-induced animal model of clonal hematopoiesis identifies inflammation as a putative driver of leukemic transformation.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the October issue: The Impact of Inflammation-induced Tumor Plasticity During #Myeloid Transformation, by Anna Yeaton, @gcayanan1, @Maguillamot, @iannisaifantis1 et al. https://t.co/oQfZNEMEAI @Perlmutter_CC @nyugrossman @nyulangone #ClonalHematopoiesis https://t.co/HSzuWiyWCd
-
-
Mashup Score: 1Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma - 2 year(s) ago
Intratumor myeloid inflammation independently predicts metastatic recurrence after nephrectomy in clear-cell renal cell carcinoma (ccRCC) and can be therapeutically targeted in a novel metastatic ccRCC mouse model.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the October issue: A Targetable #Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell #RenalCellCarcinoma, by @philrappold, @LynVuong, @arihakimi et al. https://t.co/uzYBCPTqUe @MSKCancerCenter @UrologyMSK https://t.co/MkYSnRoIc1
-
-
Mashup Score: 0Venetoclax Proves Active in Newly Diagnosed AML | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Two studies investigating the activity and safety of the BCL-2 inhibitor venetoclax support its use as part of first-line treatment in adults with newly diagnosed acute myeloid leukemia (AML). In the first study, Tapan M. Kadia, MD, of the University of Texas MD Anderson Cancer Center, and colleagues aimed to identify which patients receiving intensive chemotherapy might benefit from the addition…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#Venetoclax proves active in newly diagnosed #acute #myeloid #leukemia (#AML), according to two recent studies that support its use as part of first-line treatment in adults https://t.co/CRz9zyXjNW
-
-
Mashup Score: 2JNCCN 360 - AML - Current and Future Steps for Venetoclax Combination Therapies in AML - 2 year(s) ago
By: Celeste L. Dixon Posted: Wednesday, August 24, 2022 Initial results of combinations of the BCL2 inhibitor venetoclax with chemotherapy, immunotherapy, or targeted therapies to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are encouraging, said Shai Shimony, MD, of Dana-Farber Cancer…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JNCCN: Current and Future Steps for Venetoclax Combination Therapies in #AML and #MDS: https://t.co/5Wl5sOzTej #JNCCN360 #AMLsm #myeloi…
-
Current and Future Steps for Venetoclax Combination Therapies in #AML and #MDS: https://t.co/5Wl5sOzTej #JNCCN360 #AMLsm #myeloid #MDSsm https://t.co/j4PGQS6v3H
-
-
Mashup Score: 2Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy - Journal of Hematology & Oncology - 2 year(s) ago
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our review on #myeloid cells in #breastcancer out in #JHematolOnc. Great job by former fellow and now new @OSUCCC_James @OSUWexMed Breast Med Onc faculty Dr Kai Johnson in co-leading this review @OhioStatePIIO @Zihai #bcsm #Immunotherapy https://t.co/pfwrfWLRqY
-
-
Mashup Score: 9KiKoXP | Morphologic clues to underlying cytogenetic/molecular alterations in myeloid malignancies - 2 year(s) ago
EXCLUSIVE BLOOD ACADEMY WEBINARWho says morphology is dead and irrelevant?
Source: kikoxp.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Did you miss this @blood_academy session on #morphologic clues to underlying genetic alterations in #myeloid malignancies? Check out the link to the talk here: https://t.co/rDz9FQeDVR Be sure to subscribe to the @blood_academy youtube channel: https://t.co/DgH4LczWdn #hemepath https://t.co/XlqdOF9wDr
-
-
Mashup Score: 0Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms - 2 year(s) ago
Chemotherapy increases the mutation burden of normal blood cells in childhood cancer survivors by direct treatment-induced mutagenesis and enhanced activity of processes that are also present during healthy aging.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the August issue: Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related #Myeloid Neoplasms, by @ElineBertrums, @Axel_R_Huber, @jdekanter, @BoxtelLab et al. https://t.co/oAaFK1W8uQ @prinsesmaximac @oncodeinstitute https://t.co/oPZqHkUMPr
-
-
Mashup Score: 1Lenalidomide Linked to Risk of Therapy-Related Myeloid Neoplasms | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Prior exposure to thalidomide analogs, particularly lenalidomide, was associated with an increased risk for TP53-mutated therapy-related myeloid neoplasms (t-MNs), according to research published in Blood. Data from a multivariable analysis of the mutational profile of 416 patients with t-MNs confirmed a significant association between TP53 mutations and prior exposures to thalidomide analogs…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Prior exposure to #thalidomide analogs, particularly #lenalidomide, was associated with an increased risk for TP53-mutated therapy-related #myeloid #neoplasms (t-MNs), according to research published in @BloodJournal https://t.co/WKAG0aOsgt
-
A #liquidbiopsy used to monitor progress for patients treated with advanced solid tumors was also found to detect individuals with a high risk of developing #myeloid malignancies: https://t.co/Fxzb8cC5Dk #HemOnc https://t.co/GhNI3KbWEn